Annual Report and Accounts
For the year ended 31 March 2021
fusionantibodies.com
Annual Report and Accounts
For the year ended 31 March 2021
HEADLINES
FOR THE YEAR
COMMERCIAL ROLL | INVESTMENT IN R&D | FULL YEAR REVENUES | DEFERRED TAX |
OUT AND REVENUES | INCREASED BY 57% | INCREASED BY | ASSET OF £1.8M |
FROM RATIONAL | FROM PRIOR YEAR | 7% TO £4.2M | DERECOGNISED, BUT |
AFFINITY MATURATION | (2020: £3.9M) | TAX LOSSES OF £9.0M | |
PLATFORM (RAMPTM) | REMAIN AVAILABLE | ||
TO OFFSET FUTURE | |||
PROFITS |
LOSS FOR THE YEAR OF | £3.0M EQUITY | CASH POSITION AT THE |
£2.9M | FUNDRAISE | YEAR-END£2.7M |
(2020: LOSS £0.7M) | (2020: £1.5M) |
POST YEAR END AND
LOOKING AHEAD
RECEIPT OF FIRST
SUCCESS MILESTONE
PAYMENT OF
£150,000
FROM A KEY CLIENT
01
Fusion Antibodies plc
02
Annual Report and Accounts
For the year ended 31 March 2021
CONTENTS
STRATEGIC REPORT | |
Fusion at a glance | 4 |
Chairman's statement | 6 |
Company overview | 8 |
CEO's report and operations review | 13 |
Principal risks and uncertainties | 18 |
CORPORATE GOVERNANCE | |
Board of directors | 22 |
Corporate governance statement | 25 |
Directors' report | 31 |
FINANCIAL STATEMENTS | |
Independent auditors' report to the | 38 |
members of Fusion Antibodies plc | |
Statement of comprehensive income | 44 |
Statement of financial position | 45 |
Statement of changes in equity | 46 |
Statement of cash flows | 47 |
Notes to the financial statements | 48-65 |
Company information | 66 |
03
Attachments
- Original document
- Permalink
Disclaimer
Fusion Antibodies plc published this content on 25 August 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 01 September 2021 07:21:03 UTC.